Biotech · Private company
Integro Theranostics
Track this companyFree. Adds Integro Theranostics to your Dealase workspace and tells you when its record changes.
Clinical trials31 recruiting or active
Pipeline programs6From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline6
- LS301-IT 0.025 mg/kgPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LS301-IT 0.05 mg/kgPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LS301-IT 0.075 mg/kgPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LS301-IT 0.1 mg/kgPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LS301-IT 0.1 mg/kgPhase 2 · Non Small Cell Lung Cancer (NSCLC)ClinicalTrials.gov · fetched Nov 12, 2026
- LS301-ITPhase 1 · Lung CancersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung CancerPHASE2 · ACTIVE_NOT_RECRUITING · started Dec 8, 2025ClinicalTrials.gov NCT07276789 · fetched Nov 12, 2026
- A Single Dose, Open-Label, Dose-escalation Study of the Safety and Imaging Characteristics of LS301-IT for Intraoperative Imaging of Lung CancerPHASE1 · COMPLETED · started Nov 7, 2024ClinicalTrials.gov NCT06713564 · fetched Nov 12, 2026
- LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast CancerPHASE1_PHASE2 · COMPLETED · started Jul 14, 2023ClinicalTrials.gov NCT05900986 · fetched Nov 12, 2026